We are a global specialty and branded pharmaceutical company, improving the health of patients across the world through our high quality and affordable products. Active at every stage of the value chain, we are uniquely diversified by geography, product and manufacturing capability, positioning us well to maximise the value we create for our business and its diverse stakeholders.
We supply medicines to more than 150 countries and have 70 established business operations in 55 countries. We focus on marketing and manufacturing a broad range of post-patent, branded medicines and domestic brands covering both hospital and consumer markets.
OUR INVESTMENT CASE
Leveraging our strengths and capabilities to deliver long-term shareholder value, while living the Aspen values.
Please click on a title below left for more information.
Responsible corporate citizen and a trusted partner
- We are committed to effective and robust corporate governance making us a trusted partner. Recent high profile corporate challenges have further heightened our attention to governance and we remain committed to continuously improving our reporting, transparency and disclosure.
- We are a signatory to the United Nations Global Compact ("UN Global Compact") Initiative.
- A constituent of the FTSE/JSE Responsible Investment Index.
SHARE PRICE CENTRE
View share price information for Aspen Holdings.
APN ISIN: ZAE 000066692
JSE data delayed by 15 minutes, page refreshes every 5 minutes. Indicated trade times are actual.
Aspen Group Unaudited Interim Results presentation for the six months ended 31 December 2019
• PDF 857KB
All capital distributions to date
Analysis of shareholders at 30 June 2019
All corporate information and contact details
30 June 2020
Financial year end
10 September 2020
Year end results announcement and presentation in Johannesburg
9 December 2020
Annual General Meeting